Mentari, InMed Merge In Deal Backed By $290M Funding
law360
1 month ago
18 views
InMed Pharmaceuticals Inc. on Tuesday announced plans to merge with migraine prevention drugmaker Mentari Therapeutics Inc. in an all-stock deal that is backed by a $290 million private placement and was guided by three law firms.
Continue Reading
Sign up for FREE to read the full article and access 129K+ alternative investment headlines.